Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2024

Feb 22, 2024

33090_dirs_2024-02-21_d4d5bb9d-a8a5-4d1f-be8b-ef51989e6fda.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 0023-12-19

Reporting Person: Stelmakh Edward (CFO/COO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
0023-12-19 Stock Option $12.73 A 15711 Acquired 2026-12-19 Common Stock (15711) Direct
0023-12-19 Restricted Stock Units $ A 15711 Acquired 2026-12-19 Common Stock (15711) Direct

Footnotes

F1: The stock option vests in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date.